Abrysvo is now approved to prevent lower respiratory tract disease caused by RSV in high-risk adults over 18 years of age.

Sanofi is likely to implement a buyback, Jefferies analysts said a note. -- Key Drugs: The uptake of Sanofi's respiratory syncytial virus treatment Beyfortus will be watched, UBS analysts said. Also ...

While it’s a win for Pfizer over GSK and its RSV vaccine Arexvy, which is approved for those 50 and older, it’s difficult to ...

They are respiratory infections that cause similar symptoms such as coughing, fever and fatigue. These illnesses can range ...